NCT00086333View on ClinicalTrials.gov

FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2004

Study Completion Date

December 31, 2005

Conditions
Non-Small Cell Lung Carcinoma
Interventions
DRUG

SGN-15, Docetaxel

Trial Locations (4)

21231

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

60637

University of Chicago, Chicago

97213

Providence Health System, Regional Cancer Program, Portland

97227-1191

Kaiser Permanente, Portland

All Listed Sponsors
lead

Seagen Inc.

INDUSTRY

NCT00086333 - FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma | Biotech Hunter | Biotech Hunter